Nutra Pharma unit to publish MS research
Florida, USA-based Nutra Pharma, which is developing drugs for HIV and multiple sclerosis, says that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publication in the Critical Reviews in Immunology special conference issue.
The article, entitled Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application, discusses the background and reasoning behind ReceptoPharm's research on its treatment for MS. The company has completed Phase I studies and is preparing to begin Phase II clinical trials.
Paul Reid, chief executive of ReceptoPharm, said that "alpha-cobratoxin could play an important role in treating multiple sclerosis and we believe it is important to disseminate our research throughout the scientific community."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze